Liquid non-ionic salt-free skin and hair treatment composition that contains lauroyl n-methyl glucamide

ABSTRACT

Compositions and methods for their use in treating human or other mammalian skin and hair. Non-ionic, salt-free non-solidifying formulations of Lauroyl N methyl glucamide and alkyl glycosides are disclosed that impart beneficial barrier properties to skin and hair.

REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of co-pending U.S. Ser.No. 14/172,667 filed Feb. 4, 2014, which claims the benefit of priorityunder 35 U.S.C. §119(e) to U.S. application Ser. No. 61/760,839, filedon Feb. 5, 2013, the contents of which are incorporated in theirentirety by reference.

FIELD OF THE INVENTION

This invention relates to methods of formulating Lauryl N-MethylGlucamide for hair and skin applications. The method comprisesformulating Lauryl N-Methyl Glucamide to achieve a non-solidifying watersoluble formulation that exhibits unanticipated physical properties of anature beneficial to its application to skin surfaces or hair.

BACKGROUND OF THE INVENTION

Lauroyl N-Methyl Glucamide (D-glucitol, 1-deoxy-1-(methylamino)-,N—C10-16 acyl derivatives CAS#173145-38-5) has the structure indicatedbelow.

Lauroyl N-Methyl Glucamide (“LMG”) as described in this invention isgenerally a mixture consisting of C₁₀, C₁₂, C₁₄, C₁₆ acyl compounds. Itis a waxy, non-oily solid that melts at about 60° C. in water. Solutionsof LMG solidify into hard non-oily gels at temperatures of about 35°that resemble agar gels in feel and consistency. LMG is a member of thegroup of chemical compounds referenced to as alkyl N-Methyl glucamidesor alternatively as alkanoyl N-Methyl glucamides.

LMG-containing formulations are known to form rigid solid gels attemperatures below 10° C.; therefore, the resulting solids must besubsequently warmed to temperatures above ambient conditions (21° C.) torestore a liquid solution. Alkyl N-Methyl glucamides have beenincorporated into hair products such as mousses and shampoos (U.S. Pat.No. 6,395,258) because of the thickness (viscosity) they impart.However, the formulations disclosed (such as those described in U.S.Pat. No. 6,395,258) solidify at temperatures between 15°-20° C. (SeeExample 1), which is an unacceptable property when such phasetransitions are not permitted in a commercial product. LMG also has beenused in liquid laundry and dishwashing detergents (U.S. Pat. No.5,332,538). These detergents contain high concentrations of stronganionic detergents, which both provide the detergency required for theintended use of the product, and secondarily prevent LMG fromsolidification. An example of a liquid detergent formulation isdisclosed in U.S. Pat. No. 5,174,927:

TABLE 1 Ingredient Wt. % Coconutalkyl (C₁₂) N-methyl glucamide 14 C₁₄₋₁₅EO (2.25) sulfate, Na salt 10.0 C₁₄₋₁₅ EO (7) 4.0 C₁₂₋₁₄ alkenylsuccinicanhydride¹ 4.0 C₁₂₋₁₄ fatty acid* 3.0 Citric acid (anhydrous) 4.6Protease (enzyme)² 0.37 Termamyl (enzyme)³ 0.12 Lipolase (enzyme)⁴ 0.36Carezyme (enzyme)⁵ 0.12 Dequest 2060S⁶ 1.0 NaOH (pH to 7.6) 5.5 1,2propanediol 4.7 Ethanol 4.0 Sodium metaborate 4.0 CaCl₂ 0.014Ethoxylated tetraethylene pentamine⁷ 0.4 Brightener⁸ 0.13 Silane⁹ 0.04Soil release polymer¹⁰ 0.2 Silicone (suds control)¹¹ 0.4 Siliconedispersant¹² 0.2 Water and minors Balance

LMG has been used to increase the viscosity of cleansing compositions.U.S. Pat. No. 5,009,814 describes addition of LMG for the use inshampoo. The formulation contains a strong anionic detergent thatprovides the required cleansing activity, and the specifiedconcentration secondarily prevents LMG from solidifying.

TABLE 2 Shampoo formulations based on a paraffinsulfonic acid sodiumsalt or a paraffinsulfonic acid glucamine salt (which is gentle toskin), in combination with mixtures of thickeners Formula I II III (%)(%) (%) Paraffinsulfonic acid, 13.5 13.5 13.5 glucamine salt Marlamid ®(coconut oil 3.0 fatty acid diethanolamide N-methyl coconut oil fatty3.0 acid glucamide Antil ® (polyoxyethylene- 2.56 2.56 2.56 propyleneglycol dioleate Viscosity (mPa · S) 142 317 1,590 Paraffinsulfonic acid,13.5 13.5 13.5 sodium salt Marlamid ® 3.0 N-methyl coconut oil fatty 3.0acid glucamide Antil ® 2.56 2.56 2.56 Viscosity (mPa · S) 63 217 622

It would be advantageous for the purpose of skin and hair treatments,such as a shampoo or skin cleanser/hydrating lotions to create anaqueous formulation of LMG which is free of strong anionic detergents(which are damaging to both skin and hair) and which remain liquid attemperatures that would be experienced during storage and shipping.

SUMMARY OF THE INVENTION

The present invention is directed to a simple method of formulating LMGfor the purpose of its use on hair and skin surfaces as anon-solidifying liquid shampoo, or skin cleanser/hydrating lotionwithout the addition of ionic detergents or salts. In one embodiment themethod comprises the formulation of LMG with decyl glucoside in suchproportions that LMG does not solidify (remains liquid) at roomtemperature or below (21° C.). The addition of certain simple lowmolecular weight compounds in the correct proportions to LMG can preventthe liquid to solid phase transition. Furthermore, these LMGcompositions still retain the capacity to create a non-oily waterimpermeable barrier when applied to skin or hair.

In another embodiment, the formulation includes glycerol in addition towater and LMG.

In yet another embodiment of the invention, the formulation includesother components required to exhibit certain properties, such asviscosity enhancers, fragrances, conditioners, antibacterial agents,colorants, preservatives, silicones, anti-frizz agents.

In certain embodiments of the invention, the formulation contains LMG ata concentration between 0.5% and 30% wt/wt and decyl glucoside at aconcentration between 0.5% and 60% wt/wt, with the weight ratio of thetwo compounds (LMG to decyl glucoside) of between 2:1 and 1:3, and whichremains liquid at temperatures below 0° C.

In certain embodiments of the invention, the formulation contains LMG ata concentration between 0.5% and 30% wt/wt and decyl glucoside at aconcentration between 0.5% and 30% wt/wt, with the weight ratio of thetwo compounds (LMG to decyl glucoside) of between 2:1 and 1:1, and whichremains liquid at temperatures below 0° C.

In particular, a preferred embodiment of the invention is a formulationthat contains LMG at a concentration of between 5-15% wt/wt, e.g., about14% wt/wt, decyl glucoside at a concentration between 20% and 30% wt/wtand glycerol at about 12% wt/wt and which remains liquid at temperaturesbelow 0° C.

In another embodiment, a formulation contains LMG at a concentration ofbetween 5-15% wt/wt, e.g., about 10% wt/wt, decyl glucoside at aconcentration between 5-10% wt/wt, and glycerol at 10% wt/wt, and whichremains liquid at temperatures below 0° C.

A second preferred embodiment of the invention is a formulation thatcontains LMG at a concentration of about 3% wt/wt, decyl glucosidebetween 3-8% wt/wt, glycerol at 17% wt/wt, and which remains liquid attemperatures below 0° C.

In certain embodiments, the formulation can include LMG atconcentrations of 0.5-1.0 wt %, 1-2 wt %, 2-3 wt %, 3-4 wt %, 4-5 wt %,5-6 wt %, 6-7 wt %, 7-8 wt %, 8-9 wt %, 9-10 wt %, 10-11 wt %, 11-12 wt%, 12-13 wt %, 13-14 wt %, 14-15 wt %, 15-16 wt %, 16-17 wt %, 17-18 wt%, 18-19 wt %, 19-20 wt %, 20-21 wt %, 21-22 wt %, 22-23 wt %, 23-24 wt%, 24-25 wt %, 25-26 wt %, 26-27 wt %, 27-28 wt %, 28-29 wt % or 29-30wt %, or any combination thereof.

In certain embodiments, the formulation can include decyl glucoside atconcentrations of 0.5-1.0 wt %, 1-2 wt %, 2-3 wt %, 3-4 wt %, 4-5 wt %,5-6 wt %, 6-7 wt %, 7-8 wt %, 8-9 wt %, 9-10 wt %, 10-11 wt %, 11-12 wt%, 12-13 wt %, 13-14 wt %, 14-15 wt %, 15-16 wt %, 16-17 wt %, 17-18 wt%, 18-19 wt %, 19-20 wt %, 20-21 wt %, 21-22 wt %, 22-23 wt %, 23-24 wt%, 24-25 wt %, 25-26 wt %, 26-27 wt %, 27-28 wt %, 28-29 wt % or 29-30wt %, in combination with LMG at concentrations of 0.5-1.0 wt %, 1-2 wt%, 2-3 wt %, 3-4 wt %, 4-5 wt %, 5-6 wt %, 6-7 wt %, 7-8 wt %, 8-9 wt %,9-10 wt %, 10-11 wt %, 11-12 wt %, 12-13 wt %, 13-14 wt %, 14-15 wt %,15-16 wt %, 16-17 wt %, 17-18 wt %, 18-19 wt %, 19-20 wt %, 20-21 wt %,21-22 wt %, 22-23 wt %, 23-24 wt %, 24-25 wt %, 25-26 wt %, 26-27 wt %,27-28 wt %, 28-29 wt % or 29-30 wt %, in any combination.

In place of decyl glucoside other alkyl glycosides can be substituted.Such surfactants include but are not limited to one or more sugar-basedsurfactants, i.e. alkyl polyglycosides. The alkyl polyglycosides havethe formula (II) or Formula (III) below:

wherein R₁ is a monovalent organic radical having from about 6 to about30 carbon atoms, preferably from 6 to 12 carbon atoms, and morepreferably having an average of from 10 to 10.5 carbon atoms; Z issaccharide residue having 5 or 6 carbon atoms; and b is a number havinga value from 0 to about 12. Preferred alkyl polyglycosides which can beused in the compositions according to the invention have the formula IIwherein Z is or includes a glucose residue. Such alkyl polyglycosidesare commercially available, for example; as TRITON® GC-100, an oligomerD-glucopyranose decyl octyl glycoside from Union Carbide Corporation,and APG®, GLUCOPON®, or PLANTAREN® surfactants from Cognis Corporation,Ambler, Pa. 19002. Examples of the Cognis surfactants include but arenot limited to:

1. GLUCOPON® 225DK Surfactant—an alkyl polyglycoside in which the alkylgroup contains 8 to 10 carbon atoms and having an average degree ofpolymerization of 1.7.

2. GLUCOPON® 425N Surfactant—an alkyl polyglycoside in which the alkylgroup contains 8 to 16 carbon atoms, having an average of 10.3 carbonatoms, and having an average degree of polymerization of 1.5.

3. GLUCOPON® 625UP Surfactant—an alkyl polyglycoside in which the alkylgroup contains 12 to 16 carbon atoms and having an average degree ofpolymerization of 1.6.

4. APG® 325N Surfactant—an alkyl polyglycoside in which the alkyl groupcontains 9 to 11 carbon atoms and having an average degree ofpolymerization of 1.5.

5. GLUCOPON® 600UP Surfactant—an alkyl polyglycoside in which the alkylgroup contains 12 to 16 carbon atoms and having an average degree ofpolymerization of 1.4.

6. PLANTAREN® 2000 Surfactant—a C₈-C₁₆ alkyl polyglycoside in which thealkyl group contains 8 to 16 carbon atoms and having an average degreeof polymerization of 1.5.

7. PLANTAREN® 1300 Surfactant—a C₁₂-C₁₆ alkyl polyglycoside in which thealkyl group contains 12 to 16 carbon atoms and having an average degreeof polymerization of 1.6.

8. GLUCOPON® 220N Surfactant—an alkyl polyglycoside in which the alkylgroup contains 8 to 10 carbon atoms and having an average degree ofpolymerization of 1.5.

Other examples of alkyl polyglycosides that can be used herein includealkyl polyglycoside surfactants which are comprised of mixtures ofcompounds of formula II wherein Z represents a moiety derived from areducing saccharide containing 5 or 6 carbon atoms; b is a number havinga value from 1 to about 6; and R¹ is an alkyl radical having from 8 to20 carbon atoms. The compositions are characterized in that they haveincreased surfactant properties and an HLB in the range of about 10 toabout 16 and a non-Flory distribution of glycosides, which is comprisedof a mixture of an alkyl monoglycoside and a mixture of alkylpolyglycosides having varying degrees of polymerization of 2 and higherin progressively decreasing amounts, in which the amount by weight ofpolyglycoside having a degree of polymerization of 2 or mixtures thereofwith the polyglycoside having a degree of polymerization of 3predominate in relation to the amount of monoglycoside, said compositionhaving an average degree of polymerization of about 1.8 to about 3. Suchcompositions, also known as peaked alkyl polyglycosides, can be preparedby separation of the monoglycoside from the original reaction mixture ofalkyl monoglycoside and alkyl polyglycoside after removal of thealcohol. This separation may be carried out by molecular distillationand normally results in the removal of about 70-95% by weight of thealkyl monoglycosides. After removal of the alkyl monoglycosides, therelative distribution of the various components, mono- andpoly-glycosides, in the resulting product changes and the concentrationin the product of the polyglycosides relative to the monoglycosideincreases as well as the concentration of individual polyglycosides tothe total, i.e. DP2 and DP3 fractions in relation to the sum of all DPfractions. Such compositions are disclosed in U.S. Pat. No. 5,266,690,the entire contents of which are incorporated herein by reference.

In certain embodiments the formulation can include alkyl glycosides atconcentrations of 0.5-1.0 wt %, 1-2 wt %, 2-3 wt %, 3-4 wt %, 4-5 wt %,5-6 wt %, 6-7 wt %, 7-8 wt %, 8-9 wt %, 9-10 wt %, 10-11 wt %, 11-12 wt%, 12-13 wt %, 13-14 wt %, 14-15 wt %, 15-16 wt %, 16-17 wt %, 17-18 wt%, 18-19 wt %, 19-20 wt %, 20-21 wt %, 21-22 wt %, 22-23 wt %, 23-24 wt%, 24-25 wt %, 25-26 wt %, 26-27 wt %, 27-28 wt %, 28-29 wt % or 29-30wt %, and any combination thereof with LMG, in the concentration notedherein above.

Other examples of surfactants that can be used herein include one ormore nonionic polysorbate surfactants (polyoxyethylene fatty acidesters), obtained by the esterfication of sorbitol with one or threemolecules of a fatty acid, usually stearic, lauric, oleic, or palmiticacid, under conditions which cause splitting out of water from thesorbitol, leaving sorbitan fatty acid esters, i.e. a mixture of estersof the fatty acid with sorbitol and its mono- and di-anhydrides, andhaving a water content below 0.2%. The above ester mixture is thencondensed with varying quantities of ethylene oxide, usually about 20moles of ethylene oxide per mole of sorbitol. Examples of suchpolysorbate surfactants include, but are not limited to, Polysorbate 20(polyoxyethylene (20) sorbitan monolaurate), Polysorbate 60(polyoxyethylene (20) sorbitan monosterate), Polysorbate 80(polyoxyethylene (20) sorbitan monooleate), Polysorbate 65(polyoxyethylene (20) sorbitan tristearate), and Polysorbate 85(polyoxyethylene (20) sorbitan trioleate).

In addition to the above polysorbate surfactants, surfactant sorbitanesters can also be used, either alone or in combination with apolysorbate. Sorbitan ester surfactants include sorbitan mono esterswith fatty acid, preferably stearic, lauric, oleic, or palmitic acid.

The composition can be used by spray or direct manual application to theskin and hair.

Both the foregoing summary of the invention and the following detaileddescription of the invention are exemplary and explanatory and areintended to provide further details of the invention as claimed. Otherobjects, advantages, and novel features will be readily apparent tothose skilled in the art from the following detailed description of theinvention.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is described with reference to the following figures,which are presented for the purpose of illustration only and are notintended to be limiting of the invention.

FIG. 1 is the chemical structure of Lauroyl N-Methyl Glucamide (LMG),along with cartooned drawings of the molecule to illustrate thestructures of a micelle and an extended gel.

FIG. 2 is an illustration comparing the stable gel form of LauroylN-Methyl Glucamide (LMG) demonstrating the destabilizing effect of alkylpolyglucoside on the LMG gel.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a simple method of formulating LMGfor the purpose of its use on hair and skin surfaces, as a shampoo orskin cleanser/hydrating lotion. The method discloses the unanticipatedproperty of LMG to form films on hair and skin that create a barrier towater loss. This type of barrier will reduce water loss from damaged oraging skin (“drying”) or water absorption onto hair shafts (“frizzing”).Because LMG solidifies into a hard gel at the concentrations that areused for application to hair and skin, formulations are provided toprevent gel formation and at the same time permit the formation of thatgel in skin and on hair to create the desired barrier. We discloseherein that by mixing specific concentrations of decyl glucoside with adesired concentration of LMG a concentrated solution of LMG can beformulated in such a way as to prevent its solidification at roomtemperature to facilitate its utility as a skin and hair care product.In addition, the formulation does not contain an ionic surfactant, norany added salts, both of which negate the beneficial effects that arebeing sought. The formulation disclosed is a non-oily aqueous solutionthat imparts to the surface of skin or hair a water vapor barrier thatcompares in permeability to petrolatum, without the concomitant tactilesensations on skin.

Lauryl N-Methyl Glucamide as described in this invention is generally amixture consisting of C₁₀, C₁₂, C₁₄, C₁₆ acyl compounds. It is waxy,non-oily solid that melts at about 60° C. in water. Prior art solutionsof LMG are known to solidify into hard non-oily gels at temperaturesbelow about 35° C. that resemble agar gels in feel and consistency.

The gel forming property of this water soluble compound suggested thatLMG could be used to create a non-oily gel-based barrier on the surfaceof skin and hair. On the skin this non-oily barrier (or film) would beexpected to reduce water vapor loss, due to its hydrophobic structure.On hair, the LMG barrier would be expected to provide a non-oilyhydrophobic coating, reducing the adsorption of water vapor leading to“frizzing.” In addition, the surfactant properties of LMG would impart acleansing property to the formulation on skin and hair.

Skin and hair surfaces, composed of proteins, exhibit a negative andpositive electrostatic charges, a consequence of the presence of freecarboxylate moieties from glutamic and aspartic acid amino groups fromlysine, and guanidino groups from arginine. A skin or hair product thatcontains ionic surfactants, or ionic organic molecules, will depositthese compounds on the surface of skin or hair as a consequence of theresulting electrostatic interactions between charged amino acid sidechains of the proteins of skin and hair and the ionic components in thecomposition. This interaction will cause the organic components to beretained on the surface of the skin and hair, leaving behind a residueof these substances. These residues can interfere with the functionalityof natural protective substances produced by the skin and scalp, such asantimicrobial peptides. Antimicrobial peptides are generally shortcationic, amphipathic molecules. They are present on the surface of skinand released onto the growing hair shaft from cells within the follicle.Anionic surfactants, by virtue of their charge and amphipathic natureinteract strongly with antimicrobial peptides and neutralize theiractivity. They are generally included to enhance the cleansing orfoaming properties of the formulation. As an example, the shampoodisclosed in EP0550656B1 contains 3.5% LMG, but in addition 13.5%ammonium lauroyl sulfate, a strong anionic detergent. It would bedesirable to avoid inactivating naturally occurring protectivesubstances in a product designed to improve the health of skin and hair.Hence this invention discloses formulations that do not require theaddition of ionic surfactants.

Similarly, the absence of salts, generally included as counter-ions tobalance the charge on anionic surfactants or to increase the viscosityof solutions containing anionic surfactants, are not present or requiredin the disclosed formulations. These salts are necessarily deposited onskin and hair and are retained through ion exchange with naturallyoccurring ions. The naturally occurring antimicrobial agents depositedon hair and skin are most active in solutions at low ionic strength.Wetting the skin or hair with a solution containing salt would reducethe activity of these protective compounds, and thus interfere withtheir antimicrobial function. As an example, the shampoo disclosed inEP0550656B1 contains 3.5% LMG, but in addition 3% ammonium chloride and0.6% ammonium citrate.

At 4° C. a 0.2 wt % solution of LMG in water forms a loose jelly-likesolution. As the concentration of LMG increases the gels that are formedbecome increasingly more rigid, and the temperature at which the LMGsolution gels, decreases progressively. The gelation property isreflection of the capacity of LMG to create extensive spatially extendednetworks in solution. For the purposes of use on hair and skin,concentrations of LMG of between 5-15 wt % are preferred, which formhard gels at about 35° C. An aqueous 15% solution of LMG would be solidat room temperature (21° C.) and would require heating to bring theformulation into solution.

The structure of the LMG (Formula I) molecule explains its gel formingproperty, it being comprised of a hydrophobic acyl tail and ahydrophilic linear carbohydrate. LMG does not appear to form stablemicelles in aqueous solutions, since macroscopic aggregation occurs atconcentrations far below the critical micelle concentration that occursfor other sugar lipid based surfactants. Gel formation may result fromsimilar molecular dimensions of the hydrophobic and hydrophiliccomponents of the LMG molecule which favors a side by side packing orderrather than a spherical micelle configuration, and the hydrophobicity ofthe long chains which drives the hydrophobic aggregation, i.e. producinga layering of the molecules, representing an open packing array that cangrow indefinitely (FIG. 1). The macroscopic gel formation can occur atvery low concentrations, e.g. a 0.1% solution of N-Lauroyl-N-methylglucamide heated to 45° C. will cool to form a physically stable gelhaving considerable volume and structural rigidity.

LMG is non-ionic, water soluble, and amphipathic, and as shares physicalproperties with molecules such as ceramides which can readily permeatethe hair shaft and the stratum corneum of human and animal epidermis.Upon penetration into the intercellular matrix of the stratum corneumLMG would be expected to organize into the extended lamellar aggregatesdescribed above. These intradermal lamellar aggregates would improve thebarrier properties of the epidermis, including epidermis deficient inthe normal lipid barrier, which is known to occur in various diseasestates. On the surface of hair, a film containing LMG would be expectedto organize into gelled barrier.

In addition, since LMG is a surfactant it is able to solubilizehydrophobic proteins and lipids normally resident on the hair and in theepidermis. These include proteins and lipids contained within lamellarbodies, which can undergo physical disruption, releasing diffusiblecontents which are then absorbed into the lipid/protein matrix thatcomprises the normal epidermal barrier. Thus the artificial barriercomprised of LMG would likely soon become populated by low molecularweight proteins and lipids normally resident on the surface of healthyhair and skin.

It would be advantageous for the purpose of skin and hair use to createan aqueous formulation of LMG which remains liquid at room temperature.As noted above a solution of LMG in water would cool to a solid at roomtemperature and would require heating to melt prior to use. In thepresent invention we disclose that by the addition of specificconcentrations of an alkyl polyglycoside surfactant, preferably decylglucoside, the temperature of the liquid-solid transition can belowered. Furthermore, as we show herein, the application of this liquidformulation to skin and hair imparts a non-oily hydrophobic barrier.

Such surfactants include but are not limited to one or more sugar-basedsurfactants, i.e. alkyl polyglycosides. The alkyl polyglycosides havethe formula (II) or Formula (III) below:

wherein R₁ is a monovalent organic radical having from about 6 to about30 carbon atoms, preferably from 6 to 12 carbon atoms, and morepreferably having an average of from 10 to 10.5 carbon atoms; Z issaccharide residue having 5 or 6 carbon atoms; and b is a number havinga value from 0 to about 12. Preferred alkyl polyglycosides which can beused in the compositions according to the invention have the formula IIwherein Z is or includes a glucose residue. Such alkyl polyglycosidesare commercially available, for example; as TRITON® GC-100, an oligomerD-glucopyranose decyl octyl glycoside from Union Carbide Corporation,and APG®, GLUCOPON®, or PLANTAREN® surfactants from Cognis Corporation,Ambler, Pa. 19002. Examples of the Cognis surfactants include but arenot limited to:

1. GLUCOPON® 225DK Surfactant—an alkyl polyglycoside in which the alkylgroup contains 8 to 10 carbon atoms and having an average degree ofpolymerization of 1.7.

2. GLUCOPON® 425N Surfactant—an alkyl polyglycoside in which the alkylgroup contains 8 to 16 carbon atoms, having an average of 10.3 carbonatoms, and having an average degree of polymerization of 1.5.

3. GLUCOPON® 625UP Surfactant—an alkyl polyglycoside in which the alkylgroup contains 12 to 16 carbon atoms and having an average degree ofpolymerization of 1.6.

4. APG® 325N Surfactant—an alkyl polyglycoside in which the alkyl groupcontains 9 to 11 carbon atoms and having an average degree ofpolymerization of 1.5.

5. GLUCOPON® 600UP Surfactant—an alkyl polyglycoside in which the alkylgroup contains 12 to 16 carbon atoms and having an average degree ofpolymerization of 1.4.

6. PLANTAREN® 2000 Surfactant—a C₈-C₁₆ alkyl polyglycoside in which thealkyl group contains 8 to 16 carbon atoms and having an average degreeof polymerization of 1.5.

7. PLANTAREN® 1300 Surfactant—a C₁₂-C₁₆ alkyl polyglycoside in which thealkyl group contains 12 to 16 carbon atoms and having an average degreeof polymerization of 1.6.

8. GLUCOPON® 220N Surfactant—an alkyl polyglycoside in which the alkylgroup contains 8 to 10 carbon atoms and having an average degree ofpolymerization of 1.5.

Other examples of alkyl polyglycosides that can be used herein includealkyl polyglycoside surfactants which are comprised of mixtures ofcompounds of formula II wherein Z represents a moiety derived from areducing saccharide containing 5 or 6 carbon atoms; b is a number havinga value from 1 to about 6; and R¹ is an alkyl radical having from 8 to20 carbon atoms. The compositions are characterized in that they haveincreased surfactant properties and an HLB in the range of about 10 toabout 16 and a non-Flory distribution of glycosides, which is comprisedof a mixture of an alkyl monoglycoside and a mixture of alkylpolyglycosides having varying degrees of polymerization of 2 and higherin progressively decreasing amounts, in which the amount by weight ofpolyglycoside having a degree of polymerization of 2 or mixtures thereofwith the polyglycoside having a degree of polymerization of 3predominate in relation to the amount of monoglycoside, said compositionhaving an average degree of polymerization of about 1.8 to about 3. Suchcompositions, also known as peaked alkyl polyglycosides, can be preparedby separation of the monoglycoside from the original reaction mixture ofalkyl monoglycoside and alkyl polyglycoside after removal of thealcohol. This separation may be carried out by molecular distillationand normally results in the removal of about 70-95% by weight of thealkyl monoglycosides. After removal of the alkyl monoglycosides, therelative distribution of the various components, mono- andpoly-glycosides, in the resulting product changes and the concentrationin the product of the polyglycosides relative to the monoglycosideincreases as well as the concentration of individual polyglycosides tothe total, i.e. DP2 and DP3 fractions in relation to the sum of all DPfractions. Such compositions are disclosed in U.S. Pat. No. 5,266,690,the entire contents of which are incorporated herein by reference.

Other examples of surfactants that can be used herein include one ormore nonionic polysorbate surfactants (polyoxyethylene fatty acidesters), obtained by the esterfication of sorbitol with one or threemolecules of a fatty acid, usually stearic, lauric, oleic, or palmiticacid, under conditions which cause splitting out of water from thesorbitol, leaving sorbitan fatty acid esters, i.e. a mixture of estersof the fatty acid with sorbitol and its mono- and di-anhydrides, andhaving a water content below 0.2%. The above ester mixture is thencondensed with varying quantities of ethylene oxide, usually about 20moles of ethylene oxide per mole of sorbitol. Examples of suchpolysorbate surfactants include, but are not limited to, Polysorbate 20(polyoxyethylene (20) sorbitan monolaurate), Polysorbate 60(polyoxyethylene (20) sorbitan monosterate), Polysorbate 80(polyoxyethylene (20) sorbitan monooleate), Polysorbate 65(polyoxyethylene (20) sorbitan tristearate), and Polysorbate 85(polyoxyethylene (20) sorbitan trioleate).

In addition to the above polysorbate surfactants, surfactant sorbitanesters can also be used, either alone or in combination with apolysorbate. Sorbitan ester surfactants include sorbitan mono esterswith fatty acid, preferably stearic, lauric, oleic, or palmitic acid.

Addition of decyl glucoside reduces the liquid-solid phase transitiontemperature of an LMG solution (see Example 1). This likely occurs dueto the interspersion of the short chain alkyl sugar between the acylchains of the LMG bilayer reducing the stability of the structure (FIG.2). As the molar proportion of decyl glucoside relative to that of LMGincreases, the LMG gel structure is progressively destabilized,reflected in the decreasing melting temperature of the LMG solid phase.

The solid structure destabilizing effects of decyl glucoside can bedemonstrated in two ways: Firstly, on the temperature at which asolution of LMG solidifies; secondly, on the temperature at which an LMGsolid melts. These two processes occur at different temperatures in thecase of LMG. Thus, a 10 wt % solution of LMG solidifies at about 30° C.,and melts, once formed, at about 50° C. (Table 1 and Example 1). Ifdecyl glucoside is added to 0.5 wt %, the 10 wt % LMG solutionsolidifies at 30° C. and the solid, once formed, melts at 43° C. Byprogressively increasing the concentration of decyl glucoside to 5% andhigher, the 10% LMG solution will not solidify as the temperature fallsto −20° C., forming instead a “glass”. As the temperature rises, theglass becomes less viscous (Table 1 and Example 1).

The present formulation of LMG disclosed herein will maintain a liquidphysical state regardless of the temperatures to which the solution hadbeen exposed, and regardless of the high concentration of this compound(10%). The disclosed formulation of LMG will remain liquid at roomtemperature or below. Thus, proportions of LMG and decyl glucoside canbe adjusted specifically to insure that the formulation does not undergoa liquid to solid phase transition at low temperatures.

In contrast to the present invention, the prior art involving the use ofLMG for direct use on hair or skin does not specifically teach how toavoid solidification at temperatures below ambient conditions. Forexample, the preferred composition of U.S. Pat. No. 6,395,258, whichdescribes a hair mousse and shampoo, contains 8% LMG and 4%cocoamidylpropyl betaine as the principal components. When thisformulation was prepared and then cooled, a hard solid formed at 15° C.,and required heating to 31° C. to melt back into solution (Example 1).

Further, the disclosed formulation can be shown to exhibit barrierproperties that reduce water loss from damaged skin (Example 3) and toimpart volumizing effects on hair (Example 7).

In another embodiment of the invention the disclosed formulation can bemixed with other components to impart particular properties desired.These additives include non ionic or charged additives, one or more ofthose commonly present in cosmetics and other skin care products, suchas viscosity modifiers, e.g. thickeners; propylene glycol;1,3-butanediol; butylene glycol; ethanol; rheology modifiers, e.g.carbomers such as Carbopol® 940; emollients such as synthetic andnatural esters, hydrocarbons such as petrolatum, mineral oil,isoparaffins, and hydrocarbon waxes such as polyethylene, starches,fatty acids, silicone oils such as cyclic or linearpolydimethylsiloxanes, polyalkyl siloxanes, polyalkylarylsiloxanes, andpolyether siloxane copolymers; hydroxyethyl cellulose; betaines; otheralcohols such as stearyl alcohol and phenoxyethanol; perfumes;preservatives; other surfactants and soaps; and the like. In addition,water may be and usually is present as the remainder of the composition.The above list of skin care excipients is exemplary only and is notmeant to be limiting. Examples of other surfactants that can be used aregiven below in a disclosure of the second embodiment of the invention.

The above compositions can also contain components having a therapeuticor protective effect on the skin, including OTC pharmaceuticals andother compounds having approved FDA monographs since the compositionsenhance the absorption of such therapeutically active or protectivecompounds into the skin. Hence, conditions such as bacterial, viral, andfungal infections of the skin can be treated with the above compositionscontaining effective quantities of antiviral agents, antibiotics,antifungal agents, and mixtures thereof. Also, skin conditions requiringtreatment with acne agents, analgesics, anorectal agents, scabicides,pediculicides, antineoplastics, antirosacea agents, acne treatmentagents, antipruritics, antipsoriasis agents, depigmenting agents,topical hemostatics, wart treating agents, anti-itch agents, and thelike can be treated using the compositions of the invention containingan effective quantity of one or more of the above active therapeuticcompounds. Skin protective agents include antioxidants, antiagingactives, sun screening agents, and tanning agents. Preferred componentshaving a therapeutic or protective effect on the skin are those havingstability and efficacy over a broad pH range, e.g. between 4 and 8 or atleast between 5 and 7. Here again the remainder of the compositions isusually water.

The compositions of the invention are useful as skin and hair careproducts, e.g., they are dermatologic external preparations forapplication to skin and hair. They can be used in the form of an aqueoussolution and when skin care excipients are present they can be in theform of lotions, creams, astringents, facial packs, wrinkle-preventingeye creams, cleansing products to remove make-up, including theatricalmake-up, and body care products such as shampoos, body cleansers,including powdered facial and body cleansers, and hand washers. They canalso be used as peptizing agents for soap/syndet and syndet barproducts. They form a gel-type film on the skin surface to maintain thelipid barrier properties of the skin, and to protect against transepidermal water loss, and surprisingly are also absorbed into thestratum corneum producing a smooth silky feel to the skin, reducingdryness as well as reducing dermatitis, irritant dermatitis, and thelike.

They also can be used to reduce the visible effects of aging and/or sundamage.

Owing to their lipid properties, the compositions of the invention helpmaintain the skin barrier function, reduce skin roughness, and provide avelvety skin after feel.

In addition, the disclosed formulations are nonirritating, mild to theskin and eyes, can provide good but not excessive lathering as skincleansers, are substantive to the skin, spread easily, are nongreasy,are compatible with skin lipids, are odorless, are noncomedogenic, havean excellent shelf life, and are biodegradable.

The compositions of the invention are applied to the skin using knowncosmetic applicators, or can be applied by hand. The compositions can beremoved from the surface of the skin or left in place on the skin. Thecompositions should, however, be left in contact with the skin until theformula (I) compounds and other beneficial skin and hair care products,if present, have been absorbed into the stratum corneum or the shaft ofthe hair. This absorption usually takes place fairly rapidly, usuallywithin 5 or 10 minutes.

It has further been discovered that the above compositions can restorethe epithelial water barrier properties of damaged skin without needingto destroy or otherwise remove infectious microorganisms, includingbacteria, fungi, viruses, and yeast from the skin, e.g. by counteractingthe deleterious effects of hyphae produced by the mycelium of fungi thatattacks the skin and its water barrier, such as Tinea pedis infections,commonly referred to as athlete's foot.

Hence the damaged skin can be restored without requiring the use ofantibacterial, antiviral, and/or antifungal agents, which often havetoxic or other deleterious side effects on the skin.

EXAMPLES Example 1

A composition was prepared by dissolving 10% by weight of C₁₂/C₁₄alkanoyl-N-methyl glucamide (wherein the C₁₂ and C₁₄ alkanoyl groupswere obtained as a mixture from coconut oil), and 10% by weight glycerolin deionized water. The pH was then adjusted to 4-5 with HCl. Separatesolutions were also prepared with increasing final concentrations ofdecyl glucoside: 0.0, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0. Thecompositions were brought into clear, colorless single phase solutionsby heating to 60° C. The solutions were then cooled in a refrigeratedchamber and the temperature at which gelling occurred was noted. As theconcentration of decyl glucoside increased the temperature at which theLMG solution gelled decreased, forming a non-gelling glass at decylglucoside concentrations of 5% and above. Thus the addition of decylglucoside at concentrations of 5% or greater to a solution of 10% LMGand 10% glycerol prevents stable gel formation, even at temperatures aslow as −20° C.

TABLE 3 Temperature Decyl at which 10% LMG glucoside solution solidifies(wt %) (° C.) 0.0 35 0.5 30 1 25 2 21 3 4 4 −8 5 glass 6 glass

The solids that had formed during the cooling of the solutions were thenplaced into a warming chamber and the temperature at which the solidsmelted were determined. In the absence of the addition of decylglucoside, a solid containing 10% LMG and 10% glycerol melts at about50° C. With increasing concentrations of decyl glucoside the meltingtemperature falls, such that at 5% and higher concentrations of decylglucoside LMG does not solidify.

TABLE 4 Temperature at Decyl which a 10% glucoside LMG solid melts (wt%) (° C.) 0.0 50 0.5 43 1 37 2 31 3 25 4 21 5 glass 6 glass

This example demonstrates that it is possible to formulate LMG withdecyl glucoside to create a an LMG formulation that remains in a liquidphase at temperatures where LMG would necessarily solidify and requiremelting before use in the application to skin or hair.

A comparative example was prepared to demonstrate the effect of theformulation according to the present invention. Preferred formulationsof LMG for use as a hair mousse and cleansers were disclosed in U.S.Pat. No. 6,395,258. Composition A was preferred:

TABLE 5 % (active ingredient) A B C D E F G Amphomer — — — 1.2 — — 1.2Sodium Polyvinyl Sulfonate 0.6 0.6 — — — — — Shellac — — 0.7 — — — —Gantrez S97 (PVM/MA — — — — 0.4 0.7 — Copolymer)* Amodimethicone — — — —0.5 — — Coceth-40 — — — — 5.0 — 5.0 Undeceth-9 — — — — — 8.0 —Cocotrimonium chloride 1.5 1.5  1.75 — 1.4 1.9 2.0 N-Methyl C12/14 Alkyl8.0 8.0 8.0 12.5  — — — Glucamide Cocoamidopropyl betaine 4.0 4.0 4.02.0 8.0 4.0 8.0 Coco monoethanolamide 1.0 1.0 1.0 2.0 — 1.0 2.0 Sodiumbenzoate 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Phenoxyethanol 0.4 0.4 0.4 0.4 0.40.4 0.4 PEG 6000 Distearate — 2.5 — — — — — Ethanol — — 1.4 — — — —Fragrance 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Water to 100.0 *Neutralized withamino methyl propanol.Composition A was prepared as described in the above table.

At room temperature the solution was viscous in consistency. Thesolution solidified at 15° C. On standing at 0° C. for 1 hour it formeda hard waxy white gel that crumbled when penetrated with a probe. Theresulting solid did not melt until the temperature increased to 35° C.Thus, it is evident that compositions that include LMG and othersurfactants to achieve an optimal effect on hair or skin do notnecessarily exhibit acceptable phase stability characteristics. Suchphase transitions in a commercial product are unacceptable.

Example 2

A composition was prepared containing the following components:

Component % by weight % by weight (active) Water 70.2N-lauroyl-N-methyl- 3.74 2.62 glucamide (70% active in water)PLANTAREN ® 2000* 5.8 2.9 (50% active in water) PEG 150 distearate 0.20.2 Glycerin 17 17.0 HCl (10%) to pH 6.15 *a C₈-C₁₆ alkyl polyglycosidehaving a degree of polymerization of 1.5.

The above formulation was prepared by adding the glycerin to the waterwith stirring until clear. Then the other components were added withstirring, and the resulting mixture was heated to 50° C. with stirringuntil clear. The pH was adjusted to 6.15 with the 10% HCl. Thecomposition of Example 2 formed a viscous liquid at −20° C. whichthinned to its original viscosity as the temperature was increased toroom temperature.

Example 3 Repair of Epidermal Barrier as Measured by Trans-EpidermalWater Loss.

Transepidermal water loss, the quantitative measurement of theevaporative loss of water across the epidermis, is a well-recognizedmeasure of the integrity of the skin's hydrophobic barrier, a criticalcomponent of healthy skin structure.

The following clinical study presents a measurement of the kinetics oftransepidermal water loss recovery in patients with atopic dermatitis, askin condition associated with a damaged skin barrier, followingapplication of various compositions to the skin surface.

Two subjects were enrolled in the study. The subjects were in generalgood health, with clinically verified atopic tendencies, as determinedby a dermatologist, having compromised volar forearm skin, as determinedby Baseline Dermalab readings of 4.0 or more on each arm. Individualswith active symptoms of allergy, atopic dermatitis, active eczema,active psoriasis, sunburn, excessive scarring, tattoos, or other skincondition in the test that would interfere with the assessments of thisstudy as well as individuals with known allergies to lotions,moisturizers or other topical products were excluded from the study.

Transepidermal water loss (TEWL) were measured at Baseline(pre-composition application) and at 1, 2, 4 and 8 hourspost-application.

In this study, the Dermalab, manufactured by Cortex Technologies, inconjunction with a computer, was used to measure TEWL utilizing an openchamber system.

A hand held probe placed on the skin surface sampled relative humidityat two points above the surface, allowing the rate of water loss to becalculated from the measured humidity gradient. Each TEWL measurementwas taken over 60 seconds. Dermalab measurements were taken once on eachtest site at each time-point.

Prior to instrumental measurements, subjects rested quietly for at least20 minutes in a designated room at a temperature of 66-74° F. and 15-55%relative humidity. Indoor temperature and humidity were recorded hourlyduring the course of the study visit.

Baseline TEWL measurements were taken on each test site. Test sites weredemarcated with a surgical skin marker and were approximately 3 cm². Thebaseline Dermalab measurements were 4.0 or greater on each test site toqualify.

Qualified subjects gently washed the test sites with water and patteddry prior to composition application. Within 15 minutes of the wash,subjects had 20 micro-liters of test material applied to each test site,with one site left untreated. Test composition application wasrandomized on a site rotational basis. Subjects had Dermalabmeasurements repeated at approximately 1, 2, 4 and 8 hourspost-application.

The compositions used in the study are as follows:

-   -   water    -   composition of Example 2    -   petrolatum (positive control)

Trans-epidermal water loss (TEWL) measurements were taken using theDermalab at each test site prior to test material application (Baseline)and at 1, 2, 4, and 8 hours post-application. Table 2 presents theresults of the TEWL measurements for each test material. Mean values ateach post-application time point were statistically compared to meanBaseline values for significant differences. The average percent changefrom Baseline is listed in parentheses.

TABLE 6 MEAN VALUES FOR TEWL MEASUREMENTS (n = 2) Baseline 1 Hour Post-2 Hours Post- 4 Hours Post- 8 Hours Post- (Pre-Application) ApplicationApplication Application Application Water 5.03 4.47 4.74 4.37 6.00Composition of 5.03 2.64 3.07 3.50 3.41 Example 2 Petrolatum - 4.67 1.912.30 3.00 3.06 Positive Control

From a statistical analysis of the mean TEWL values measured as afunction of time after test formulation application, it is evident thatCompositions of Example 2 cannot be distinguished from petrolatum withrespect to repair of the TEWL property of atopic skin. In contrast, wecan be 95% certain that water was less effective than petrolatum in thisstudy.

TEWL values for normal healthy skin range between 2 and 3 ul/cm²/hr. Thebaseline values for the patients included in this study ranged between5.03 and about 6.7, indicative of skin with a damaged water barrier.Treatment with petrolatum resulted in a rapid and sustained improvementin the TEWL. The values achieved with petrolatum, between 1.9 (1 hr)rising to about 3 (8 hrs) represents the “normal” values characterizingthis experimental setting. It is evident that the composition of Example2 achieved normal or near normal TEWL values, comparable to petrolatum.

Example 4

A clinical trial was conducted to assess the efficacy to deliver andretain moisture to the skin after a single application of thecomposition of Example 2 by use of the Corneometer CM 825, the Skincon200 EX. 8 subjects were enrolled. Each had mild to moderate dry skin onthe lower legs. Measurements were taken in triplicate at baseline, 1hour, 3 hours, and 6 hours post-application. The Corneometer quantifiesthe moisture content of the stratum corneum using an electricalcapacitance method. The Skincon quantifies the moisture content using anelectrical conductance method.

TABLE 7 Pre- 1 hour 3 hours  6 hours application post post postCorneometer Example 2 30.69  66.30*  58.44*  55.64* No treatment 29.5633.25 32.32 34.88 Skincon Example 2 44 293*   233*   217*   No treatment42 50   49   48   *Statistically significant (p < 0.05) increasecompared to baseline

This Example demonstrates that the formulation of Example 2 exhibitssignificant hydrating properties when applied to dry or damaged skin.

Example 5

Treatment of Tinea pedis infections with the composition of Example 2compared to treatment with LAMISIL® cream.

Superficial fungal infections of the skin are amongst the most commoninfections in man. Current treatment universally involves administrationof an antifungal compound applied locally to the affected skin site, ortaken orally to provide systemic delivery. In addition, frequentlyfungal infections recur repeatedly on an infected site, requiring therepeated use of antifungal compounds, many of which have deleteriousside effects.

The pathophysiology of the superficial infections caused bydermatophytes is reasonably well understood in its broad outlines. 1)Fungal organisms gain a foothold on the most superficial layers of skin;2) The fungi secrete a broad range of hydrolytic enzymes includingproteases and lipid degrading enzymes that damage the epidermal barrier;3) The fungal products subsequently provoke inflammation as theypenetrate the proliferative basal layer; and 4) hyper proliferation,associated with local inflammation, scaling, itching and secondarybacterial infection results.

A two-week clinical usage study was conducted with the composition ofExample 2 and LAMISIL® cream. During the course of the study, subjectshaving a Tinea pedis infection, i.e. having a positive KOH test and thepresence of athlete's foot on one or both feet, as determined by a scoreof 1 or greater for interdigital erythema and pruritus and/orburning/stinging, applied one of the following treatments as determinedby a randomization design to a target foot selected by the studyphysician twice a day:

Composition of Example 4-8 subjects

LAMISIL® cream (OTC)—10 subjects

Clinic evaluations were conducted at Baseline (Visit 1), Week 1 (Visit2), and Week 2 (Visit 3). Subjects participated in the followingprocedures at the indicated visits:

Clinical Grading of Irritation Parameters: Baseline, Week 1, Week 2

The selected target lesion was clinically graded by the study physicianfor following parameters:

-   -   Objective irritation (clinically graded): Erythema,        Cracking/Fissuring, Scaling, and Pruritus    -   Subjective irritation (assessed by subjects): Burning/Stinging

Target Foot Global Assessment: Week 1, Week 2

The study physician performed a global assessment of the target foot forthe improvement of signs and symptoms.

Self-Assessment Questionnaire: Baseline, Week 1, Week 2

Subjects completed a Baseline self-assessment questionnaire regardingtheir perceptions of the severity of athlete's foot symptoms, includingredness, pain, and interference with daily activities.

KOH Staining: Baseline, Week 2

The target area was scraped and transferred to a slide for potassiumhydroxide (KOH) staining. The slide was examined to determine thepresence of fungal hyphae.

Informed Consent

Written informed consent conforming to 21 CFR 50.25 was obtained fromeach subject prior to enrollment in the study.

Procedures and Methods

At Baseline (Visit 1), prospective subjects with self-perceivedathlete's foot completed an Eligibility and Health Questionnaire andsigned an Informed Consent Agreement and Confidentiality Agreement. Thestudy physician (Board Certified Podiatrist) examined subjects' feet andselected a target foot and a target lesion on the selected foot to betracked during the study. The location of the target lesion was markedon a body site map.

Subjects participated in the following Baseline/qualificationprocedures:

Clinical Grading

The selected target lesion was clinically graded by the study physicianfor following parameters using the indicated scales:

-   -   Objective irritation (clinically graded): Erythema,        Cracking/Fissuring, Scaling, Pruritus    -   Subjective irritation (assessed by subjects): Burning/Stinging        -   0=None        -   1=Mild        -   2=Moderate        -   3=Severe        -   (Half-point scores were used as necessary)

KOH Staining

The target area was scraped and transferred to a slide for potassiumhydroxide (KOH) staining. The slide was examined to determine thepresence of fungal hyphae.Subjects qualified for study participation by having a positive KOH testand the presence of athlete's foot on one or both feet, as determined bya score of 1 or greater for interdigital erythema and pruritus and/orburning/stinging. Qualified subjects participated in the followingprocedures:

Self-Assessment Questionnaire

Subjects completed a Baseline self-assessment questionnaire regardingtheir perceptions of the severity of athlete's foot symptoms, includingredness, pain, and interference with daily activities.Subjects were assigned to one of the following treatments according to apre-determined randomization design:

LAMISIL® Cream (OTC) Composition of Example 2

Subjects were instructed to shower at least once daily and apply theassigned test material to both feet twice per day, each morning andprior to bedtime, as follows:

LAMISIL® Cream (OTC): Apply to affected areas of the foot as instructedby manufacturer.

Composition of Example 2:

Apply three pumps of lotion to the affected foot.

Dispense lotion into the palm of cupped hand and work the liquid intothe feet between the toes, on the sole, and around the sites of footuntil entire foot is covered with lotion.Let feet dry for at least five minutes prior to covering feet (withsocks, shoes, hosiery, bed sheets, etc.).

Subjects were provided with written usage instructions, a calendar ofstudy visits, and a daily diary to record test material applicationtimes and comments.

Subjects returned to the clinic at Week 1 (Visit 2) and Week 2 (Visit3). Subjects participated in the following procedures at each visit asindicated:

Daily diaries were reviewed for compliance and subjects were questionedregarding changes in their health status and medications.

Subjects completed a self-assessment questionnaire regarding theseverity of athlete's foot symptoms.

The study physician graded subject's selected target lesion forobjective and subjective irritation parameters as described forBaseline.

The study physician also performed a global assessment of the targetfoot using the following scale:

1=Clear: 100% remission of clinical signs and symptoms

2=Excellent: 80-99% improvement from Baseline

3=Good: 50-79% improvement from Baseline

4=Fair: 25-49% improvement form Baseline

5=Poor: less than 25% improvement from Baseline

6=Worse: clinical signs and symptoms worse than Baseline

At Week 2 only, the target lesion was scraped and transferred to a slidefor KOH staining, which was examined to confirm the presence of fungalhyphae.

Subjects returned completed diaries and test material units to theclinic at the completion of Visit 3. Test material units were weighedfor compliance.

Biostatistics and Data Management

Mean values for clinical grading parameters and self-assessmentquestionnaires at Week 1 and Week 2 were statistically compared to meanBaseline values using a paired t-test at the p≦0.05 significance level.Mean percent change and incidence of improvement were calculated for allattributes. Comparisons were made among the three treatments usinganalysis of variance (ANOVA) with paired comparisons (Fisher's LSD).Results for target foot global assessment grading at Week 1 and Week 2,and for KOH staining at Week 2 were tabulated and a top box analysis wasperformed. Fisher's Exact Test (2-sided) was used to determine betweentreatment comparisons.

Results

At Baseline, Week 1, and Week 2, the selected target lesion wasclinically graded for objective and subjective irritation parameters.Table 8 presents the results of the clinical grading for each treatment.Mean values at Week 1 and Week 2 are statistically compared to meanBaseline values. The average percent change from Baseline is listed inparentheses.

TABLE 8 MEAN VALUES FOR CLINICAL GRADING OF TARGET LESION IRRITATIONPARAMETERS Baseline Week 1 Week 2 (Visit 1) (Visit 2) (Visit 3)LAMISIL ® Erythema 0.75 0.35 (−53.3%) 0.45 (−40.0%) Cream (OTC)Crackling/Fissuring 0.70 0.35 (−50.0%) 0.30 (−57.1%) (n = 10) Scaling1.05 1.25 (19.0%) 0.85 (−19.0%) Pruritus 2.00 0.45* (−77.5%) 0.20*(−90.0%) Burning/Stinging 1.55 0.40* (−74.1%) 0.00* (−100%) CompositionErythema 1.25 1.00 (−20.0%) 0.69 (−45.0%) of Example 2Crackling/Fissuring 0.69 0.63 (−9.0%) 0.31 (−54.5%) Scaling 1.06 0.81(−23.5%) 0.69* (−35.2%) Pruritus 2.13 1.00* (−52.9%) 0.31* (−85.2%)Burning/Stinging 1.00 0.31* (−68.7%) 0.19* (−81.2%) *Indicates astatistically significant (p ≦ 0.05) decrease (improvement) compared toBaseline

Results of ANOVA Comparisons for Irritation Grading

Comparisons based on the average change from Baseline, were made amongthe two treatments for irritation parameter grading. Results of thecomparisons showed no statistically significant (p≦0.05) differencesamong the three treatments for any graded objective or subjectiveirritation parameter.

At Week 1 and Week 2, the study physician performed a global assessmentof the target foot. The Table below presents the results of the targetfoot global assessment for each treatment. The number and percentage ofsubjects with each score is presented, and the p-value indicatingstatistical significance between the positive and negative scores isalso listed.

TABLE 9 RESULTS OF TABULATIONS FOR TARGET FOOT GLOBAL ASSESSMENTSLAMISIL ® Composition of Cream (OTC) Example 2 (n = 10) (n = 8) Week 1Week 2 Week 1 Week 2 1 = Clear: 100% remission of 0 (0.0%)  1 (10.0%) 0(0.0%)  1 (12.5%) clinical signs and symptoms 2 = Excellent: 80-99%improvement 2 (20.0%) 4 (40.0%) 1 (12.5%) 3 (37.5%) from Baseline 3 =Good: 50-79% improvement 2 (20.0%) 4 (40.0%) 3 (37.5%) 1 (12.5%) fromBaseline 4 = Fair: 25-49% improvement 5 (50.0%) 0 (0.0%)  2 (25.0%) 3(37.5%) from Baseline 5 = Poor: less than 25% improvement 0 (0.0%)  1(10.0%) 2 (25.0%) 0 (0.0%)  from Baseline 6 = Worse: clinical signs and1 (10.0%) 0 (0.0%)  0 (0.0%)  0 (0.0%)  symptoms worse than BaselinePositive Grades: Score of 1, 2, 3 4 (40.0%) 9 (90.0%) 4 (50.0%) 5(62.5%) Negative Grades: Score of 5 and 6 1 (10.0%) 1 (10.0%) 2 (25.0%)0 (0.0%)  p-value: 0.180 0.011 0.414 0.025

A significantly greater proportion of subjects received a positive score(1, 2, 3) than negative score (5, 6) for LAMISIL® Cream and theComposition of Example 8 at Week 2.

Results of Comparisons for Target Foot Global Assessment

Fisher's Exact Test (2-sided) was used for between treatment comparisonsbetween positive and negative grades. Results of the comparisons showedno statistically significant differences between the two treatments fortarget foot global assessment at Week 1 and Week 2.

At Baseline, Week 1, and Week 2, subjects completed a self-assessmentquestionnaire regarding their perceptions of the severity of theirathlete's foot symptoms using the following scales:

TABLE 10 0 3 6 9 1. What is the severity of your athlete's foot Not atMild Moderate Severe    symptoms all 2. How red and inflamed (overall,on average) do    you feel your condition is 3. Howpainful/uncomfortable are your symptoms Not at Somewhat Moderately/Extremely 4. Do you feel this condition interferes with your all Fairly   daily activities

The Table below presents the results of the self-assessmentquestionnaire analysis for each treatment. Mean values at Week 1 andWeek 2 are statistically compared to mean Baseline values. The averagepercent change from Baseline is listed in parentheses.

TABLE 11 MEAN VALUES FOR SELF-ASSESSMENT QUESTIONNAIRES Baseline Week 1Week 2 (Visit 1) (Visit 2) (Visit 3) LAMISIL ® Cream 1. Severity ofsymptoms 5.30 4.20* (−20.7%) 3.10* (−41.5%) (OTC) 2. Red and inflamed5.20 3.10* (−40.3%) 2.60* (−50.0%) (n = 10) 3. Painful/uncomfortable4.80 2.60* (−45.8%) 2.00* (−58.3%) 4. Daily activities interference 3.501.60* (−54.2%)  1.70 (−51.4%) Composition of 1. Severity of symptoms6.00 4.38* (−27.0%) 2.88* (−52.0%) Example 4 2. Red and inflamed 5.503.13* (−43.1%) 2.63* (−52.2%) 3. Painful/uncomfortable 4.75 3.00*(−36.8%) 2.00* (−57.8%) 4. Daily activities interference 4.25 2.63*(−38.2%)  2.25 (−47.0%) *Indicates a statistically significant (p ≦0.05) decrease (improvement) compared to Baseline.

Results of ANOVA Comparisons for Self-Assessment Questionnaires

Comparisons, based on the average change from Baseline, were made amongthe two treatments for self-assessment questions. Results of thecomparisons showed no statistically significant (p≦0.05) differencesamong the two treatments for any of the self-assessment questions.

At Baseline and Week 2, the target area of each subject was scraped andtransferred to a slide for potassium hydroxide (KOH) staining, and theslide was examined to determine the presence of fungal hyphae. Allsubjects tested positive for KOH staining at Baseline in order toqualify for the study. The Table below presents the results of the KOHstaining at Week 2. The number and percentage of subjects with apositive and negative stain is presented, and the p-value indicatingstatistical significance between the positive and negative stainpercentages is also listed.

TABLE 12 RESULTS OF TABULATIONS FOR KOH STAINING AT WEEK 2 LAMISIL ®Cream Composition of (OTC) Example 4 (n = 10) (n = 8) Positive (+) 1(10.0%) 6 (75.0%) Negative (−) 9 (90.0%) 2 (25.0%) p-value 0.11 0.157A significantly greater proportion of subjects had a negative stain thana positive stain for LAMISIL® Cream at Week 2.

Results of Comparisons for KOH Staining at Week 2

Fisher's Exact Test (2-sided) was used for between treatment comparisonsbetween positive and negative stains. Results of the comparisons showedthat there was a statistically significant (p=0.012) difference betweenthe two treatments for KOH staining.

Discussion and Conclusions

The following table shows the statistically significant decreases(improvements) compared to Baseline for each test treatment:

TABLE 13 LAMISIL ® Composition Cream (OTC) of Example 2 (n = 10) (n = 8)Week 1 Week 2 Week 1 Week 2 Erythema Crackling/Fissuring Scaling *Pruritus * * * * Burning/Stinging * * * * * Indicates a statisticallysignificant (p ≦ 0.05) decrease (improvement) compared to Baseline.

Comparisons between the two treatments showed no statisticallysignificant differences for clinical grading of target lesion irritationparameters.

Target Foot Global Assessment

At Week 1 and Week 2, the study physician performed a global assessmentof the target foot for the improvement of signs and symptoms compared toBaseline. Results of the tabulations for target foot global assessmentshowed that a significantly greater proportion of subjects received apositive score (1, 2, 3) than negative score (5, 6) for LAMISIL® Creamand for the Composition of Example 2 at Week 2. Comparisons among thetwo treatments showed no statistically significant differences betweenpositive and negative scores for target foot global assessment.

Self-Assessment Questionnaire

At Baseline, Week 1, and Week 2, subjects completed a Baselineself-assessment questionnaire regarding their perceptions of theseverity of athlete's foot symptoms, including redness, pain, andinterference with daily activities. Results of the self-assessmentquestionnaire analysis showed a statistically significant decrease(improvement) in the following questions at the indicated time pointsfor each treatment:

TABLE 14 LAMISIL ® Composition Cream (OTC) of Example 2 Week 1 Week 2Week 1 Week 2 1. Severity of symptoms * * * * 2. Red andinflamed * * * * 3. Painful/uncomfortable * * * * 4. DailyActivities * * * Indicates a statistically significant (p ≦ 0.05)decrease (improvement) compared to Baseline.Comparisons among the two treatments showed no statistically significantdifferences for self-assessment questions.

KOH Staining

At Baseline and Week 2, the target area was scraped and transferred to aslide for KOH staining. The slide was examined to determine the presenceof fungal hyphae. All subjects tested positive for KOH staining atBaseline in order to qualify for the study. At Week 2, a significantlygreater proportion of subjects had a negative stain than positive stainfor LAMISIL® Cream. Results of the comparisons among the two treatmentsshowed that there was a statistically significant (p=0.012) differencefor KOH staining.

It is clear from this study that the formulation of Example 2 achievedclinical improvements and resolution of confirmed T. pedis infectionscomparable to LAMISIL® cream, a commercial product. Despite the modestreduction in the presence of dermatophytes, clinical benefit wasobserved, suggesting that the dermatophytes were now simply colonizingthe skin rather than behaving as pathogens. Since the composition ofExample 2 possesses little or no antimicrobial activity nor activityagainst dermatophytes, the clinical resolution of the T. pedis infectionmust have occurred through a secondary effect on the skin itself, i.e.the compositions of this embodiment create a hydrophobic gel barrierwithin the stratum corneum, thus physically separating the microbes andtheir noxious products from the underlying skin tissues. Standardhydrophobic creams coat the superficial layers of the skin, thus sealingthe microbes within the barrier.

Example 6

A composition was prepared containing the following components:

Component % by weight (active) Water 48 LMG (96% active in water) 14PLANTAREN ®2000* 25 (50% active in water) PEG 150 distearate 0.9Glycerin 12 HCl to pH 6.0 1

Example 7

A composition of Example 6 was placed into a −20° C. freezer, and withinseveral hours formed a glass. Warming to room temperature restored theliquid to its original viscosity.

The composition was applied as a shampoo to wet hair. The compositionlathered well. The composition did not remove coloring dye from treatedhair. After drying the hair was noticeably soft and lustrous. Exposureof the washed and dried hair to steam vapor did not cause frizzing,suggesting that a water barrier had been imparted to the hair shafts.Continued weekly use over the course of several weeks appeared to reducehair breakage and hair loss.

1. An aqueous composition free of ionic surfactants for use as a shampooor skin cleanser/hydrating lotion, consisting essentially of an aqueousformulation of Lauroyl N-methyl-glucamide (LMG) at a concentrationbetween 0.5% and 30% by weight and alkyl polyglycoside at aconcentration of between 0.5% and 30% by weight, with the weight ratioof the two compounds LMG and alkyl polyglycoside of between 2:1 and 1:3and which remains liquid at temperatures below 0° C., where the alkylpolyglycoside has the formula (II) or Formula (III) below:

wherein R₁ is a monovalent organic radical having from about 6 to about30 carbon atoms, preferably from 6 to 12 carbon atoms; Z is saccharideresidue having 5 or 6 carbon atoms; and b is a number having a value of12 or less.
 2. The composition of claim 1, wherein the weight ratio ofLMG and alkyl glucoside is between 2:1 and 1:3 and which remains liquidat temperatures below 0° C.
 3. The composition of claim 1, wherein z isor includes a glucose residue.
 4. The composition of claim 1, whereinthe composition includes one or more additives selected rom viscositymodifiers, fragrances, preservatives, silicones, essential oils,conditioners, and therapeutic agents.
 5. The composition of claim 1,wherein the composition includes glycerol.
 6. The composition of claim1, wherein the composition contains Lauroyl methyl-glucamide at aconcentration of about 5-15% by weight, decyl glucoside between 20-30%by weight and glycerol between 5-25% by weight and which remains liquidat temperatures below 0° C.
 7. The composition of claim 1, wherein thecomposition contains Lauroyl methyl-glucamide contains at aconcentration of about 5-15%, decyl glucoside between 5-10% and glycerolbetween 5-25% and which remains liquid at temperatures below 0° C. 8.The composition of claim 1, wherein the composition contains Lauroylmethyl-glucamide at a concentration of about 3% by weight, decylglucoside is between 3-8% by weight, glycerol is at 17% by weight, andwhich remains liquid at temperatures below 0° C.
 9. The composition ofclaim 1, wherein the composition contains Lauroyl methyl-glucamide at aconcentration of about 10% by weight, decyl glucoside of about 5% byweight, glycerol at 12% by weight, and which remains liquid attemperatures below 0° C.
 10. A method of fortifying or repairing theepidermal water barrier of animal skin comprising applying to the animalskin on effective quantity of the composition of claim
 1. 11. The methodof claim 10, wherein the animal is human.
 12. The method of claim 11,wherein the human skin is infected with a fungus infection.
 13. A methodof fortifying or repairing the water barrier of hair comprising applyingto the animal skin on effective quantity of the composition of claim 1.14. The method of claim 13, wherein the animal is human.
 15. The methodof claim 14, wherein the human skin is infected with a fungus infection.